TY - JOUR
T1 - Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1
AU - Kito, Fumiko
AU - Oyama, Rieko
AU - Noguchi, Rei
AU - Hattori, Emi
AU - Sakumoto, Marimu
AU - Endo, Makoto
AU - Kobayashi, Eisuke
AU - Yoshida, Akihiko
AU - Kawai, Akira
AU - Kondo, Tadashi
N1 - Funding Information:
We thank Drs. Y. Minami, K. Shimizu, T. Mori, T. Uehara M. Sugawara, Y. Araki, S. Toki, T. Hirose, J. Sugaya, and Ms. R. Nakano, Division of Musculoskeletal Oncology, National Cancer Center Hospital, for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical assistance by Mrs. A. Sei, Division of Rare Cancer Research. We would like to thank Editage ( www.editage.jp ) for English-language editing and their constructive comments on the manuscript. This research was financially supported by the National Cancer Center Research and Development Fund (Grant no. 29-A-2), and technically assisted by the Fundamental Innovative Oncology Core in the National Cancer Center.
Funding Information:
We thank Drs. Y. Minami, K. Shimizu, T. Mori, T. Uehara M. Sugawara, Y. Araki, S. Toki, T. Hirose, J. Sugaya, and Ms. R. Nakano, Division of Musculoskeletal Oncology, National Cancer Center Hospital, for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical assistance by Mrs. A. Sei, Division of Rare Cancer Research. We would like to thank Editage (www.editage.jp) for English-language editing and their constructive comments on the manuscript. This research was financially supported by the National Cancer Center Research and Development Fund (Grant no. 29-A-2), and technically assisted by the Fundamental Innovative Oncology Core in the National Cancer Center.
Publisher Copyright:
© 2019, Japan Human Cell Society and Springer Japan KK, part of Springer Nature.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Extraskeletal osteosarcoma (ESOS) is a rare mesenchymal malignancy producing osteoid and bone in soft tissue without skeletal attachment. ESOS exhibits chemoresistance and poor prognosis, and is distinct from osseous osteosarcoma. The biological characteristics of ESOS are not fully understood, and patient-derived cell lines of ESOS are not available from public cell banks. Here, we established a novel cell line of ESOS and characterized its genetic and biological characteristics as well as examined its response to anti-cancer reagents. The cell line was established using tumor tissue from a 58-year-old female patient with ESOS, and named as NCC-ESOS1-C1. Phenotypes relevant to malignancy such as proliferation and invasion were examined in vitro, and genetic features were evaluated using the NCC Oncopanel assay. The response to inhibitors was monitored by screening of an anti-cancer reagent library. The cells constantly proliferated, showing spheroid formation and invasion capabilities. The NCC Oncopanel revealed the presence of actionable mutations in PIK3CA. Library screening revealed the presence of anti-cancer reagents with significant anti-proliferative effects on NCC-ESOS1-C1 at a low concentration. In conclusion, we established and characterized a novel ESOS cell line, NCC-ESOS1-C1. This cell line will be a useful resource for basic research and preclinical studies.
AB - Extraskeletal osteosarcoma (ESOS) is a rare mesenchymal malignancy producing osteoid and bone in soft tissue without skeletal attachment. ESOS exhibits chemoresistance and poor prognosis, and is distinct from osseous osteosarcoma. The biological characteristics of ESOS are not fully understood, and patient-derived cell lines of ESOS are not available from public cell banks. Here, we established a novel cell line of ESOS and characterized its genetic and biological characteristics as well as examined its response to anti-cancer reagents. The cell line was established using tumor tissue from a 58-year-old female patient with ESOS, and named as NCC-ESOS1-C1. Phenotypes relevant to malignancy such as proliferation and invasion were examined in vitro, and genetic features were evaluated using the NCC Oncopanel assay. The response to inhibitors was monitored by screening of an anti-cancer reagent library. The cells constantly proliferated, showing spheroid formation and invasion capabilities. The NCC Oncopanel revealed the presence of actionable mutations in PIK3CA. Library screening revealed the presence of anti-cancer reagents with significant anti-proliferative effects on NCC-ESOS1-C1 at a low concentration. In conclusion, we established and characterized a novel ESOS cell line, NCC-ESOS1-C1. This cell line will be a useful resource for basic research and preclinical studies.
UR - http://www.scopus.com/inward/record.url?scp=85073989556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073989556&partnerID=8YFLogxK
U2 - 10.1007/s13577-019-00291-z
DO - 10.1007/s13577-019-00291-z
M3 - Article
C2 - 31625124
AN - SCOPUS:85073989556
SN - 0914-7470
VL - 33
SP - 283
EP - 290
JO - Human Cell
JF - Human Cell
IS - 1
ER -
